A Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (Responsivity) of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 30 Jan 2019 Status changed from not yet recruiting to completed.
- 13 Mar 2018 Planned initiation date changed from 1 Dec 2017 to 15 Apr 2018.
- 21 Oct 2017 New trial record